|
|
|
|
|
|
Sponsored by: |
Merck |
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00325455 |
To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
Condition | Intervention | Phase |
Hypercholesterolemia Mixed Hyperlipemia |
Drug: MK0859 |
Phase II |
MedlinePlus related topics: | Cholesterol |
ChemIDplus related topics: | Diphtheria-Pertussis-Tetanus Vaccine Meningococcal Vaccines |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V501 Given Concomitantly With Menactra(TM) and ADACEL(TM) in Healthy Adolescents 11-17 Years of Age |
Enrollment: | 500 |
Study Start Date: | June 2006 |
Study Completion Date: | February 2007 |
Primary Completion Date: | February 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2006_006, MK0859-003 |
First Received: | May 11, 2006 |
Last Updated: | April 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00325455 |
Health Authority: | United States: Food and Drug Administration |
|
|